Stock 688488 JIANGSU AIDEA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangsu Aidea Pharmaceutical Co., Ltd.

Equities

688488

CNE1000041S6

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
14.78 CNY -1.66% Intraday chart for Jiangsu Aidea Pharmaceutical Co., Ltd. -3.40% +18.15%
Apr. 25 Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 23 Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 10,416 6,539 4,427 5,264
Enterprise Value (EV) 1 9,635 5,939 4,149 5,235
P/E ratio 248 x -222 x -35.1 x -69.1 x
Yield 0.19% - - -
Capitalization / Revenue 36 x 25.6 x 18.1 x 12.8 x
EV / Revenue 33.3 x 23.2 x 17 x 12.7 x
EV / EBITDA 174 x -167 x -29.9 x -86.4 x
EV / FCF 1,066 x -73.2 x -21.2 x -22.5 x
FCF Yield 0.09% -1.37% -4.73% -4.44%
Price to Book 7.66 x 4.99 x 3.69 x 4.68 x
Nbr of stocks (in thousands) 420,000 420,000 420,000 420,783
Reference price 2 24.80 15.57 10.54 12.51
Announcement Date 4/14/21 4/14/22 4/14/23 4/15/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 276.9 345.2 289.1 255.7 244.2 411.4
EBITDA 1 16.9 54.27 55.35 -35.46 -138.7 -60.57
EBIT 1 -3.014 32.68 33.77 -62.34 -171.6 -102.2
Operating Margin -1.09% 9.47% 11.68% -24.38% -70.28% -24.83%
Earnings before Tax (EBT) 1 7.538 38.15 47.18 -42.27 -142.4 -92.08
Net income 1 8.618 33.65 39.77 -29.99 -124.2 -76.07
Net margin 3.11% 9.75% 13.76% -11.73% -50.86% -18.49%
EPS - 0.0900 0.1000 -0.0700 -0.3000 -0.1810
Free Cash Flow 1 -153.4 -0.1099 9.035 -81.12 -196.1 -232.6
FCF margin -55.4% -0.03% 3.13% -31.72% -80.28% -56.55%
FCF Conversion (EBITDA) - - 16.33% - - -
FCF Conversion (Net income) - - 22.72% - - -
Dividend per Share - - 0.0480 - - -
Announcement Date 6/29/20 6/29/20 4/14/21 4/14/22 4/14/23 4/15/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 19.6 2.49 - - - -
Net Cash position 1 - - 781 600 278 28.8
Leverage (Debt/EBITDA) 1.159 x 0.0459 x - - - -
Free Cash Flow 1 -153 -0.11 9.04 -81.1 -196 -233
ROE (net income / shareholders' equity) 1.66% 6.24% 4.15% -2.25% -9.9% -6.54%
ROA (Net income/ Total Assets) -0.28% 2.74% 1.89% -2.7% -6.94% -3.75%
Assets 1 -3,129 1,227 2,099 1,109 1,789 2,027
Book Value Per Share - 1.550 3.240 3.120 2.850 2.670
Cash Flow per Share - 0.3600 0.5800 1.050 0.3200 0.5400
Capex 1 89.5 33.5 42.4 94.8 140 71.2
Capex / Sales 32.32% 9.7% 14.68% 37.07% 57.45% 17.31%
Announcement Date 6/29/20 6/29/20 4/14/21 4/14/22 4/14/23 4/15/24
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
JIANGSU AIDEA PHARMACEUTICAL CO., LTD. Stock Jiangsu Aidea Pharmaceutical Co., Ltd.
+18.15% 859M
CSL LIMITED Stock CSL Limited
-3.79% 87.06B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.25B
BIOGEN INC. Stock Biogen Inc.
-17.49% 31.09B
UCB Stock UCB
+54.88% 24.74B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.13% 15.91B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-15.45% 11.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.32% 8.73B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688488 Stock
  4. Financials Jiangsu Aidea Pharmaceutical Co., Ltd.